Sahibjot Sran

Sahibjot Sran

Auto-generated profile, based on publicly available information

Sahibjot Sran

Institute for Genomic Medicine, Nationwide Children’s Hospital, Columbus, OH 43215, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2023 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
KMKatherine E. Miller
Katherine E. Miller
ARAdithe C. Rivaldi
Adithe C. Rivaldi
NSNoriyuki Shinagawa
Noriyuki Shinagawa
SSSahib Sran
Sahib Sran
JNJason B. Navarro
Jason B. Navarro
TBTracy A. Bedrosian
Tracy A. Bedrosian

4 March 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
RMRobert G. Mealer
Robert G. Mealer
JAJames J. Anderson
James J. Anderson
SSSheridan L. Smith
Sheridan L. Smith
BMBrianna M. Masters
Brianna M. Masters
SBSamuel H. Barth
Samuel H. Barth
TBTracy A. Bedrosian
Tracy A. Bedrosian
Rare germline and somatic variants in SLC35A2 cause a spectrum of severe glycosylation disorders that commonly present with epilepsy. SLC35A2 encodes the Golgi transporter for UDP-galactose, but how its deficiency leads to severe neurodevelopmental disorders is unknown. Using a mouse model deficient for Slc35a2 in the forebrain, we identified a specific defect in O-GalNAc glycan synthesis, while other galactose-containing glycoconjugates remained intact. O-GalNAc glycans were absent from their normal location within neuronal tracts of the corpus callosum, and truncated precursors accumulated in the cortex on critical extracellular matrix molecules. Cultured primary neurons lacking Slc35a2 showed impaired development, hyperexcitability, and impaired O-GalNAc glycosylation. Finally, human brain tissue from cases of SLC35A2 -associated intractable epilepsy displayed a strong correlation between variant burden and truncated O-GalNAc glycans. These findings provide a mechanistic link between genetic causes of SLC35A2 -associated epilepsy and protein O-glycosylation that can be targeted for biomarker and therapeutic development.